Systemic immune‐inflammation index predicts the combined clinical outcome after sequential therapy with abiraterone and docetaxel for metastatic castration‐resistant prostate cancer patients

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0045|78|4|250-256

ISSN： 0270-4137

Source： THE PROSTATE, Vol.78, Iss.4, 2018-03, pp. : 250-256

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration‐resistant prostate cancer who progress after docetaxel and abiraterone treatment

By  

CANCER, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 270-4137, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

Optimal sequencing of docetaxel and abiraterone in men with metastatic castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1814-1820

John Wiley & Sons Inc

Access to resources Recommend Favorite

High neutrophil‐to‐lymphocyte ratio predicts poor clinical outcome in patients with castration‐resistant prostate cancer treated with docetaxel chemotherapy

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 9, 2015-09 ,pp. : 827-833

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial Comment to High neutrophil‐to‐lymphocyte ratio predicts poor clinical outcome in patients with castration‐resistant prostate cancer treated with docetaxel chemotherapy

By  

INTERNATIONAL JOURNAL OF UROLOGY, Vol. 22, Iss. 9, 2015-09 ,pp. : 834-834

John Wiley & Sons Inc

Access to resources Recommend Favorite